Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Siga Technologies (NASDAQ: SIGA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Volatility and Risk Vanda Pharmaceuticals has a
WASHINGTON, Nov. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that "NEREUS™ – The Goat of Biscayne Bay" is arriving during Miami Art Week, offering a floating activation on Biscayne Bay for people who experience motion sickness. The activation celebrates NEREUS™ (tradipitant), the first new prescription treatment for the prevention of motion-induced vomiting in more than 40 years.
WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in November 2026: The 8th Annual Wolfe Research Healthcare Conference in New York City on Tuesday, November 10, 2026. The Stifel 2026 Healthcare Conference in New York City on Wednesday, November 11, 2026.
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals NASDAQ: VNDA reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to specialty-pharmacy purchasing and shipment timing. The company also said operating expenses declined 18% from the second quarter as certain late-stage development and launch-preparation activities concluded.
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago.
Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026 Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026 Announced positive results from the Phase III study of NEREUS™ for prevention of GLP-1-induced vomiting NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 BYSANTI™ commercial launch expected in Q4 2026 Quimilza™ BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026 WASHINGTON, Oct. 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026. "We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude," said Mihael H.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6% (83/164) (p=0.002); 35% relative reduction Frequent multi-day vomiting (>2 episodes on more than one day): 6.3% (9/142) vs 15.9% (26/164) (p=0.008); 60% relative reduction Extreme vomiting (>10 total episodes): 2.8% (4/142) vs 14.6% (24/164) (p=0.0003); 81% relative reduction WASHINGTON, Oct. 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive results from Study 3601 (VP-VLY-686-3601), a Phase III randomized, placebo-controlled study evaluating NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting associated with GLP-1 receptor agonist therapy. The study showed significant reduction in overall vomiting episodes (27% p=0.006 as well as reduction of frequent (60% p=0.008) and extreme vomiting (81% p=0.0003) episodes.
Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October 28, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2026, during which management will discuss the third quarter 2026 financial results and other corporate activities.